User:Mr. Ibrahem/Remifentanil
From Wikipedia, the free encyclopedia
Remifentanil, sold under the brand name Ultiva among others, is an opioid medication used to treat during anesthesia to manage pain.[1] It is given by injection into a vein.[1] Effects begin within 90 seconds and last up to 15 minutes.[1]
![]() | |
Clinical data | |
---|---|
Trade names | Ultiva, others |
Other names | methyl 1-(2-methoxycarbonylethyl)-4-(phenyl-propanoyl-amino)-piperidine-4-carboxylate |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Opioid[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Not applicable (intravenous administration) |
Protein binding | 70% (bound to plasma proteins) |
Metabolism | cleaved by non-specific plasma and tissue esterases |
Onset of action | Within 90 sec[1] |
Elimination half-life | 1-20 minutes |
Duration of action | Up to 15 minutes[1] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C20H28N2O5 |
Molar mass | 376.453 g·mol−1 |
3D model (JSmol) | |
Melting point | 5 °C (41 °F) |
| |
| |
(verify) |
Common side effects include respiratory depression (decreased breathing), slow heart rate, low blood pressure, stiff muscles, nausea, and itchiness.[1] Breastfeeding is not recommended for 24 hours after use.[2] It works by activating the mu opioid receptor.[1]
Remifentanil was approved for medical use in the United States in 1996.[1] It is available as a generic medication.[2] In the United Kingdom 1 mg costs the NHS about £5 as of 2021.[1] In the United States this amount costs about 55 USD.[3] In the United States it is classified as a Schedule II controlled substance.[1]